Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization.

Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization.

Antimalarial drugs have usually been first deployed in areas of malaria endemicity at doses which were too low, particularly for high-risk groups such as young children and pregnant women. This may accelerate the emergence and spread of resistance, thereby shortening the useful life of the drug, but...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoir:	White, N
Formáid:	Journal article
Teanga:	English
Foilsithe / Cruthaithe:	2013

Míreanna comhchosúla

Use of population pharmacokinetic‐pharmacodynamic modelling to inform antimalarial dose optimization in infants
de réir: Banda, CG, et al.
Foilsithe / Cruthaithe: (2024)

Pharmacokinetics and pharmacodynamics of antimalarial drugs in pregnant women
de réir: Kloprogge, F
Foilsithe / Cruthaithe: (2013)

Population Pharmacokinetics and Antimalarial Pharmacodynamics of Piperaquine in Patients With Plasmodium vivax Malaria in Thailand.
de réir: Tarning, J, et al.
Foilsithe / Cruthaithe: (2014)

Population pharmacokinetics and antimalarial pharmacodynamics of piperaquine in patients with plasmodium vivax malaria in Thailand
de réir: Tarning, J, et al.
Foilsithe / Cruthaithe: (2014)

Assessment of the pharmacodynamic properties of antimalarial drugs in vivo.
de réir: White, N
Foilsithe / Cruthaithe: (1997)

Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance.
de réir: Simpson, J, et al.
Foilsithe / Cruthaithe: (2000)

Pharmacokinetic and Pharmacodynamic Considerations of Antibiotic Use in Neonates
de réir: Mario Regazzi, et al.
Foilsithe / Cruthaithe: (2023-12-01)

Pharmacokinetic and pharmacodynamic considerations with psychiatric disorders and migraines
de réir: Emma C. Palmer, PharmD, BCPS, BCPP, et al.
Foilsithe / Cruthaithe: (2024-06-01)

Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine.
de réir: White, N, et al.
Foilsithe / Cruthaithe: (1999)

Antimalarial pharmacokinetics and treatment regimens.
de réir: White, N
Foilsithe / Cruthaithe: (1992)

Clinical pharmacokinetics of antimalarial drugs.
de réir: White, N
Foilsithe / Cruthaithe: (1985)

Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study.
de réir: Nosten, F, et al.
Foilsithe / Cruthaithe: (1990)

CLINICAL IMPORTANCE OF ANTIMALARIAL PHARMACOKINETICS
de réir: Karbwang, J, et al.
Foilsithe / Cruthaithe: (1988)

Population pharmacokinetics of the antimalarial amodiaquine: A pooled analysis to optimize dosing
de réir: Ali, A, et al.
Foilsithe / Cruthaithe: (2018)

Pharmacokinetic and pharmacodynamic principles: unique considerations for optimal design of neonatal clinical trials
de réir: Cindy Hoi Ting Yeung, et al.
Foilsithe / Cruthaithe: (2024-01-01)

Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivatives.
de réir: White, N
Foilsithe / Cruthaithe: (1994)

Pharmacokinetics and metabolism of the antimalarial piperaquine after intravenous and oral single doses to the rat.
de réir: Tarning, J, et al.
Foilsithe / Cruthaithe: (2008)

Population pharmacokinetic/pharmacodynamic modeling of the psychedelic experience induced by N,N‐dimethyltryptamine – Implications for dose considerations
de réir: Emma Eckernäs, et al.
Foilsithe / Cruthaithe: (2022-12-01)

Dosing optimization of rituximab for primary membranous nephropathy by population pharmacokinetic and pharmacodynamic study
de réir: Hao Liang, et al.
Foilsithe / Cruthaithe: (2024-03-01)

Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective
de réir: Félicien Le Louedec, et al.
Foilsithe / Cruthaithe: (2020-10-01)

The pharmacokinetics and pharmacodynamics of esomeprazole in sheep after intravenous dosing
de réir: Joe S. Smith, et al.
Foilsithe / Cruthaithe: (2023-05-01)

Pharmacokinetics and pharmacodynamics of repeat dosing of gabapentin in adult horses
de réir: Jenifer R. Gold, et al.
Foilsithe / Cruthaithe: (2022-03-01)

Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses
de réir: Jose M. Serra López-Matencio, et al.
Foilsithe / Cruthaithe: (2021-10-01)

Dose optimisation based on pharmacokinetic/pharmacodynamic target of tigecycline
de réir: Bing Leng, et al.
Foilsithe / Cruthaithe: (2021-06-01)

Clinical pharmacokinetics and pharmacodynamics of artemether-lumefantrine
de réir: White, N, et al.
Foilsithe / Cruthaithe: (1999)

Improving pharmacokinetic-pharmacodynamic modeling to investigate anti-infective chemotherapy with application to the current generation of antimalarial drugs.
de réir: Katherine Kay, et al.
Foilsithe / Cruthaithe: (2013-01-01)

Loading dose in antimalarial prophylaxis.
de réir: White, N
Foilsithe / Cruthaithe: (1985)

Key considerations based on pharmacokinetic/pharmacodynamic in the design of antibody-drug conjugates
de réir: Yangyang Gao, et al.
Foilsithe / Cruthaithe: (2025-01-01)

Pharmacokinetic and Pharmacodynamic Considerations for the Use of Monoclonal Antibodies in the Treatment of Bacterial Infections
de réir: Shun Xin Wang-Lin, et al.
Foilsithe / Cruthaithe: (2018-01-01)

Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis
de réir: Deshpande, D, et al.
Foilsithe / Cruthaithe: (2018)

Optimizing Antimicrobial Therapy by Integrating Multi-Omics With Pharmacokinetic/Pharmacodynamic Models and Precision Dosing
de réir: Hui-Yin Yow, et al.
Foilsithe / Cruthaithe: (2022-06-01)

Dosing time optimization of antihypertensive medications by including the circadian rhythm in pharmacokinetic-pharmacodynamic models.
de réir: Javiera Cortés-Ríos, et al.
Foilsithe / Cruthaithe: (2022-11-01)

Pharmacokinetic determinants of the window of selection for antimalarial drug resistance.
de réir: Stepniewska, K, et al.
Foilsithe / Cruthaithe: (2008)

Considerations for Optimizing Dosing of Immunoglobulins Based on Pharmacokinetic Evidence
de réir: Iftekhar Mahmood, et al.
Foilsithe / Cruthaithe: (2020-06-01)

Lefamulin dosing optimization using population pharmacokinetic and pharmacokinetic/pharmacodynamic assessment in Chinese patients with community-acquired bacterial pneumonia
de réir: Xingchen Bian, et al.
Foilsithe / Cruthaithe: (2024-10-01)

Pharmacokinetics and pharmacodynamics of curcumin.
de réir: Sharma, R, et al.
Foilsithe / Cruthaithe: (2007)

Pharmacokinetic and pharmacodynamic considerations for treating sarcoptic mange with cross-relevance to Australian wildlife
de réir: Kotaro Takano, et al.
Foilsithe / Cruthaithe: (2023-04-01)

Dose Optimization of Combined Linezolid and Fosfomycin against Enterococcus by Using an In Vitro Pharmacokinetic/Pharmacodynamic Model
de réir: Jun Mao, et al.
Foilsithe / Cruthaithe: (2021-12-01)

Pharmacokinetic evaluation and metabolite characterization of the antimalarial piperaquine in the rat
de réir: Tarning, J, et al.
Foilsithe / Cruthaithe: (2007)

Isavuconazole Pharmacokinetics and Pharmacodynamics in Children
de réir: Hirsh Elhence, et al.
Foilsithe / Cruthaithe: (2022-12-01)